The Pediatric Growth Hormone Deficiency Patient Journey: Identifying Opportunities for Digital Health Interventions

Guido Giunti1,2, Fulvio Michelis3, Ammar Halabi3

  • 1University of Oulu, Oulu, Finland.

Insights

A new patient journey map for pediatric growth hormone deficiency (PGHD) identifies key challenges. This map offers insights for improving care and long-term outcomes for children with PGHD.

Area of Science:

  • Pediatric Endocrinology
  • Patient Experience Research
  • Digital Health

Background:

  • Pediatric growth hormone deficiency (PGHD) is a chronic condition impacting growth and development.
  • Understanding the patient journey is crucial for identifying unmet needs and improving care.
  • No comprehensive patient journey map currently exists for PGHD.

Purpose of the Study:

  • To develop the first detailed patient journey map for pediatric growth hormone deficiency (PGHD).
  • To identify key challenges and emotional sensitivities experienced by patients and caregivers throughout the PGHD journey.
  • To pinpoint opportunities for targeted interventions to enhance care and improve long-term outcomes.

Main Methods:

  • Secondary data analysis of interviews and focus groups from 62 patients and caregivers across five European countries.
  • Utilized a prototype digital health solution to guide discussions.
  • Applied grounded theory methodology for data analysis.

Main Results:

  • Developed a six-stage patient journey map for PGHD: awareness, diagnosis, treatment planning, treatment initiation, treatment maintenance, and transition.
  • Revealed specific emotional sensitivities and challenges at each stage of the journey.
  • Highlighted areas for potential intervention to improve patient adherence and outcomes.

Conclusions:

  • The developed PGHD patient journey map provides a novel framework for understanding the patient experience.
  • Identified critical points for intervention can lead to enhanced support and better management of PGHD.
  • This research offers valuable insights for healthcare providers, policymakers, and digital health developers aiming to improve care for children with PGHD.

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
20.4K
Issues And Trends In Healthcare Delivery System01:29

Issues And Trends In Healthcare Delivery System

The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.6K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
145